Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease Merja T. Augustin, MD, Jorma Kokkonen, MD,

What drives prescription patterns in pediatric asthma management?

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Serum granzymes and CD30 are increased in children's milk protein sensitive enteropathy and celiac disease Merja T. Augustin, MD, Jorma Kokkonen, MD,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy Akihiko.

Alalia Berry, MD, William W. Busse, MD

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Disparities in allergic disease: Hypersensitivity and social disorders

Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema Dagmar Simon, MD, Jennifer Wittwer, MD, Ganna Kostylina,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL- 5 and IL-5 receptor levels Miguel L. Stein, MD, Joyce M. Villanueva,

Long-term immune reconstitution after matched unrelated hematopoietic stem cell transplantation for immunodeficiency Vy Hong-Diep Kim, MD, Brenda Reid,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

The National Biome Initiative: An allergy perspective

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Phillip Lieberman, MD, Michael Tankersley, MD

A survivor: The eosinophil as a regulator in asthma

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

Ovalbumin content of influenza vaccines

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma Kawa Amin, PhD, Christer Janson, MD, PhD, Ilkka Harvima, MD,

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Personalized asthma therapy in blacks—the role of genetic ancestry

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

News & Notes Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy Akihiko.

The Editors' Choice Journal of Allergy and Clinical Immunology

Risk of oral food challenges

Eosinophilic esophagitis treated with immunotherapy to dust mites

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis Iris M. Otani, MD, Arjun A. Anilkumar,

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

The Editors' Choice Journal of Allergy and Clinical Immunology

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

Lisa A. Beck, MD, Sarbjit Saini, MD

Safety and efficacy of repeated monthly carboplatin desensitization

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma Naomi Tsurikisawa, MD, Hiroshi Saito,

Presentation transcript:

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD, Ilka Brachmann, MD, Andrea C. Klucken, MD, Jörg Kleine-Tebbe, MD, Simone Rosseau, MD, Gert Kunkel, MD, Norbert Suttorp, MD, Joachim Seybold, MD Journal of Allergy and Clinical Immunology Volume 117, Issue 6, Pages 1493-1499 (June 2006) DOI: 10.1016/j.jaci.2006.02.028 Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Eosinophil apoptosis. Individual values at baseline and week 12 of omalizumab therapy. The omalizumab group (n = 9) demonstrated a significant decrease in Annexin-positive eosinophils compared with placebo (n = 10). In the omalizumab-treated group, a significant decrease of Annexin-positive eosinophils comparing baseline with 12 weeks of treatment was found. Horizontal bars represent medians. ∗∗P < .01. Journal of Allergy and Clinical Immunology 2006 117, 1493-1499DOI: (10.1016/j.jaci.2006.02.028) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Intracellular GM-CSF in T lymphocytes. Individual values at baseline and week 12 of omalizumab therapy in (A) GM-CSF+/CD3+ lymphocytes, (B) GM-CSF+CD3/CD4+ lymphocytes, and (C) GM-CSF+CD3/CD8+ lymphocytes. Horizontal bars represent medians. ∗∗P < .01; ∗P < .05. Journal of Allergy and Clinical Immunology 2006 117, 1493-1499DOI: (10.1016/j.jaci.2006.02.028) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Intracellular IL-2 in T lymphocytes. Individual values at baseline and week 12 of omalizumab therapy in (A) IL-2+CD3+ lymphocytes, (B) IL-2+CD3/CD4+ lymphocytes, and (C) IL-2+CD3/CD8+ lymphocytes. Horizontal bars represent medians. ∗∗P < .01; ∗P < .05. Journal of Allergy and Clinical Immunology 2006 117, 1493-1499DOI: (10.1016/j.jaci.2006.02.028) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 4 Intracellular IL-13 in T lymphocytes. Individual values at baseline and week 12 of omalizumab in (A) IL-13+CD3+ lymphocytes, (B) IL-13+CD3/CD4+ lymphocytes, and (C) IL-13+CD3/CD8+ lymphocytes. Horizontal bars represent medians. ∗∗P < .01; ∗P < .05. Journal of Allergy and Clinical Immunology 2006 117, 1493-1499DOI: (10.1016/j.jaci.2006.02.028) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions